April 13, 2026

198. Beyond LDL: The 2026 Guidelines Make Lp(a), ApoB & 30-Year Risk Essential

198. Beyond LDL: The 2026 Guidelines Make Lp(a), ApoB & 30-Year Risk Essential
The player is loading ...
198. Beyond LDL: The 2026 Guidelines Make Lp(a), ApoB & 30-Year Risk Essential
Apple Podcasts podcast player badge
Spotify podcast player badge
Castro podcast player badge
RSS Feed podcast player badge
Apple Podcasts podcast player iconSpotify podcast player iconCastro podcast player iconRSS Feed podcast player icon

Darsh and Altamash unpack the first major ACC/AHA lipid update since 2018, now reframed as a dyslipidemia guideline expanding beyond LDL to include triglycerides, ApoB, and lipoprotein(a). They highlight earlier prevention, the new PREVENT risk calculator, return of numeric LDL and non-HDL targets, routine Lp(a) screening, stepwise therapy beyond statins, and greater use of CAC imaging. Using a “trucks and cargo” analogy, they clarify lipid markers, review therapies from statins to PCSK9 inhibitors and inclisiran, compare CTA vs CAC, and explain why most supplements show no benefit.

TOPICS COVERED

• What changed in the new cholesterol guidelines
• Why earlier prevention matters for lifetime risk
• New PREVENT calculator for estimating risk
• Understanding LDL, ApoB, and “bad cholesterol” markers
• Lipoprotein(a): the genetic cholesterol risk to check once
• New LDL targets and when to treat more aggressively
• Medication options beyond statins
• When to use calcium score (CAC) scans
• CTA vs CAC: which heart scan to choose
• Do supplements actually help cholesterol?

RESOURCES & LINKS MENTIONED

Connect with Us:

Ready to stop guessing and start performing? Dr. Raja is now seeing patients through his telemedicine practice—limited founding member spots available at refininghealthrx.com.